- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Organigram Launches Their First Pure CBD Cannabis Oil
Organigram Holdings announced the addition of a pure CBD edible oil product to their lineup of offerings.
Organigram Holdings (TSXV:OGI; OTCQB:OGRMF) announced the addition of a pure CBD edible oil product to their lineup of offerings.
As quoted in the press release:
This pure CBD product is a first for Organigram, complementing the company’s existing line of medical cannabis oil products.
Cannabinoids are the chemical compounds unique to cannabis that act upon the human body’s cannabinoid receptors. There are over 80 known cannabinoids present in the cannabis plant, each with varying effects. CBD (or Cannabidiol) is the second most prevalent cannabinoid in cannabis. Research has shown that CBD provides a therapeutic or calming effect without contributing to the “high” associated with Tetrahydrocannabinol (or THC), the psychoactive compound in cannabis.
“Patients are unique and require different products that help in different ways” says Greg Engel, CEO, Organigram. “As a result, we recognize the need to continually innovate and enhance both our processes and products. Today we are proud to extend our product offering and introduce Shubie Cannabis Oil as an option for patients who will benefit from its pure CBD formulation.”
Click here to read the full press release.
Source: www.marketwired.com
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.